{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [], "OtherAbstract": [], "SpaceFlightMission": [], "InvestigatorList": [], "CitationSubset": [], "OtherID": [], "GeneralNote": [], "PMID": "38617602", "DateRevised": {"Year": "2024", "Month": "04", "Day": "25"}, "Article": {"Language": ["eng"], "ELocationID": ["10.1021/acsomega.3c08148"], "ArticleDate": [{"Year": "2024", "Month": "03", "Day": "27"}], "Journal": {"ISSN": "2470-1343", "JournalIssue": {"Volume": "9", "Issue": "14", "PubDate": {"Year": "2024", "Month": "Apr", "Day": "09"}}, "Title": "ACS omega", "ISOAbbreviation": "ACS Omega"}, "ArticleTitle": "New Theobromine Apoptotic Analogue with Anticancer Potential Targeting the EGFR Protein: Computational and <i>In Vitro</i> Studies.", "Pagination": {"StartPage": "15861", "EndPage": "15881", "MedlinePgn": "15861-15881"}, "Abstract": {"AbstractText": ["The aim of this study was to design and examine a novel epidermal growth factor receptor (EGFR) inhibitor with apoptotic properties by utilizing the essential structural characteristics of existing EGFR inhibitors as a foundation.", "The study began with the natural alkaloid theobromine and developed a new semisynthetic derivative (<b>T-1-PMPA</b>). Computational ADMET assessments were conducted first to evaluate its anticipated safety and general drug-likeness. Deep density functional theory (DFT) computations were initially performed to validate the three-dimensional (3D) structure and reactivity of <b>T-1-PMPA</b>. Molecular docking against the EGFR proteins was conducted to investigate <b>T-1-PMPA</b>'s binding affinity and inhibitory potential. Additional molecular dynamics (MD) simulations over 200 ns along with MM-GPSA, PLIP, and principal component analysis of trajectories (PCAT) experiments were employed to verify the binding and inhibitory properties of <b>T-1-PMPA</b>. Afterward, <b>T-1-PMPA</b> was semisynthesized to validate the proposed design and <i>in silico</i> findings through several <i>in vitro</i> examinations.", "DFT studies indicated <b>T-1-PMPA</b>'s reactivity using electrostatic potential, global reactive indices, and total density of states. Molecular docking, MD simulations, MM-GPSA, PLIP, and ED suggested the binding and inhibitory properties of <b>T-1-PMPA</b> against the EGFR protein. The <i>in silico</i> ADMET predicted <b>T-1-PMPA</b>'s safety and general drug-likeness. <i>In vitro</i> experiments demonstrated that <b>T-1-PMPA</b> effectively inhibited EGFR<sup>WT</sup> and EGFR<sup>790m</sup>, with IC<sub>50</sub> values of 86 and 561 nM, respectively, compared to Erlotinib (31 and 456 nM). <b>T-1-PMPA</b> also showed significant suppression of the proliferation of HepG2 and MCF7 malignant cell lines, with IC<sub>50</sub> values of 3.51 and 4.13 \u03bcM, respectively. The selectivity indices against the two cancer cell lines indicated the overall safety of <b>T-1-PMPA</b>. Flow cytometry confirmed the apoptotic effects of <b>T-1-PMPA</b> by increasing the total percentage of apoptosis to 42% compared to 31, and 3% in Erlotinib-treated and control cells, respectively. The qRT-PCR analysis further supported the apoptotic effects by revealing significant increases in the levels of Casp3 and Casp9. Additionally, <b>T-1-PMPA</b> controlled the levels of TNF\u03b1 and IL2 by 74 and 50%, comparing Erlotinib's values (84 and 74%), respectively.", "In conclusion, our study's findings suggest the potential of <b>T-1-PMPA</b> as a promising apoptotic anticancer lead compound targeting the EGFR."], "CopyrightInformation": "\u00a9 2024 The Authors. Published by American Chemical Society."}, "AuthorList": [{"Identifier": ["0000-0002-6955-2263"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo 11884, Egypt."}], "LastName": "Eissa", "ForeName": "Ibrahim H", "Initials": "IH"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo 11884, Egypt."}], "LastName": "Yousef", "ForeName": "Reda G", "Initials": "RG"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Sciences, College of Pharmacy, AlMaarefa University, Riyadh 13713, Saudi Arabia."}], "LastName": "Elkaeed", "ForeName": "Eslam B", "Initials": "EB"}, {"Identifier": ["0000-0003-4497-5013"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Sciences, College of Pharmacy, Princess Nourah bint Abdulrahman University, P.O. Box 84428, Riyadh 11671, Saudi Arabia."}], "LastName": "Alsfouk", "ForeName": "Aisha A", "Initials": "AA"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Chemistry Department, Faculty of Science, New Valley University, El-Kharja 72511, Egypt."}], "LastName": "Husein", "ForeName": "Dalal Z", "Initials": "DZ"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Biophysics Department, Faculty of Science, Cairo University, Giza 12613, Egypt."}], "LastName": "Ibrahim", "ForeName": "Ibrahim M", "Initials": "IM"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Biochemistry and Molecular Biology Department, Faculty of Pharmacy, Al-Azhar University, Cairo 11884, Egypt."}], "LastName": "Ismail", "ForeName": "Ahmed", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo 11884, Egypt."}], "LastName": "Elkady", "ForeName": "Hazem", "Initials": "H"}, {"Identifier": ["0000-0001-8566-1980"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmacognosy and Medicinal Plants Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo 11884, Egypt."}, {"Identifier": [], "Affiliation": "Biopharmaceutical Products Research Department, Genetic Engineering and Biotechnology Research Institute, City of Scientific Research and Technological Applications (SRTA-City), Alexandria 21934, Egypt."}], "LastName": "Metwaly", "ForeName": "Ahmed M", "Initials": "AM"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "United States", "MedlineTA": "ACS Omega", "NlmUniqueID": "101691658", "ISSNLinking": "2470-1343"}, "CoiStatement": "The authors declare no competing financial interest."}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Siegel R. L.; Miller K. D.; Fuchs H. E.; Jemal A. Cancer statistics, 2022. Ca-Cancer J. Clin. 2022, 72 (1), 7\u201333. 10.3322/caac.21708.", "ArticleIdList": ["10.3322/caac.21708", "35020204"]}, {"Citation": "Khan F.; Akhtar S.; Kamal M. A. Nanoinformatics and Personalized Medicine: An Advanced Cumulative Approach for Cancer Management. Curr. Med. Chem. 2023, 30 (3), 271\u2013285. 10.2174/0929867329666220610090405.", "ArticleIdList": ["10.2174/0929867329666220610090405", "35692148"]}, {"Citation": "Voss A. K.; Strasser A. The essentials of developmental apoptosis. F1000Research 2020, 9, 14810.12688/f1000research.21571.1.", "ArticleIdList": ["10.12688/f1000research.21571.1", "PMC7047912", "32148779"]}, {"Citation": "Carneiro B. A.; El-Deiry W. S. Targeting apoptosis in cancer therapy. Nat. Rev. Clin. Ooncol. 2020, 17 (7), 395\u2013417. 10.1038/s41571-020-0341-y.", "ArticleIdList": ["10.1038/s41571-020-0341-y", "PMC8211386", "32203277"]}, {"Citation": "Goel S.; Hidalgo M.; Perez-Soler R. EGFR inhibitor-mediated apoptosis in solid tumors. J. Exp. Ther. Oncol. 2007, 6 (4), 305\u2013320.", "ArticleIdList": ["18038764"]}, {"Citation": "Gong Y.; Somwar R.; Politi K.; Balak M.; Chmielecki J.; Jiang X.; Pao W. Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas. PLoS Med. 2007, 4 (10), e29410.1371/journal.pmed.0040294.", "ArticleIdList": ["10.1371/journal.pmed.0040294", "PMC2001209", "17927446"]}, {"Citation": "Rosenkranz A. A.; Slastnikova T. A. Epidermal Growth Factor Receptor: Key to Selective Intracellular Delivery. Biochemistry (Moscow) 2020, 85 (9), 967\u20131092. 10.1134/S0006297920090011.", "ArticleIdList": ["10.1134/S0006297920090011", "33050847"]}, {"Citation": "Kaufman N. E. M.; Dhingra S.; Jois S. D.; Vicente M. Molecular Targeting of Epidermal Growth Factor Receptor (EGFR) and Vascular Endothelial Growth Factor Receptor (VEGFR). Molecules 2021, 26 (4), 107610.3390/molecules26041076.", "ArticleIdList": ["10.3390/molecules26041076", "PMC7922143", "33670650"]}, {"Citation": "Normanno N.; Bianco C.; De Luca A.; Salomon D. S. The role of EGF-related peptides in tumor growth. Front. Biosci. 2001, 6 (3), 685\u2013707. 10.2741/Normano.", "ArticleIdList": ["10.2741/Normano", "11333208"]}, {"Citation": "Spano J. P.; Lagorce C.; Atlan D.; Milano G.; Domont J.; Benamouzig R.; Attar A.; Benichou J.; Martin A.; Morere J. F.; Raphael M.; Penault-Llorca F.; Breau J. L.; Fagard R.; Khayat D.; Wind P. Impact of EGFR expression on colorectal cancer patient prognosis and survival. Ann. Oncol. 2005, 16 (1), 102\u2013108. 10.1093/annonc/mdi006.", "ArticleIdList": ["10.1093/annonc/mdi006", "15598946"]}, {"Citation": "Tripathi S. K.; Pandey K.; Rengasamy K. R. R.; Biswal B. K. Recent updates on the resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors and resistance reversion strategies in lung cancer. Med. Res. Rev. 2020, 40 (6), 2132\u20132176. 10.1002/med.21700.", "ArticleIdList": ["10.1002/med.21700", "32596830"]}, {"Citation": "da Rosa R.; Schenkel E. P.; Campos Bernardes L. S. Semisynthetic and newly designed derivatives based on natural chemical scaffolds: Moving beyond natural products to fight Trypanosoma cruzi. Phytochem. Rev. 2020, 19, 105\u2013122. 10.1007/s11101-020-09659-8.", "ArticleIdList": ["10.1007/s11101-020-09659-8"]}, {"Citation": "Tan S.; Lu R.; Yao D.; Wang J.; Gao P.; Xie G.; Liu H.; Yao X. Identification of LRRK2 Inhibitors through Computational Drug Repurposing. ACS Chem. Neurosci. 2023, 14, 481\u2013493. 10.1021/acschemneuro.2c00672.", "ArticleIdList": ["10.1021/acschemneuro.2c00672", "36649061"]}, {"Citation": "Deng J. N.Computer-Aided\nDrug Design. In Current Drug Synthesis, 1st\nEdition; Li J. L., Ed.; 2022, pp 339\u2212372. https://doi.org/10.1002/9781119847281.ch18"}, {"Citation": "Lin X.; Li X.; Lin X. A Review on Applications of Computational Methods in Drug Screening and Design. Molecules 2020, 25 (6), 137510.3390/molecules25061375.", "ArticleIdList": ["10.3390/molecules25061375", "PMC7144386", "32197324"]}, {"Citation": "Bertaccini E. J. Anesthesia, Coming of Age in the World of Modern In Silico Drug Design. Anesthesiology 2023, 138, 129\u2013131. 10.1097/aln.0000000000004445.", "ArticleIdList": ["10.1097/aln.0000000000004445", "36629466"]}, {"Citation": "Cohen N. C.Guidebook on Molecular Modeling in Drug Design; Gulf Professional Publishing, 1996."}, {"Citation": "Keith J. A.; Vassilev-Galindo V.; Cheng B.; Chmiela S.; Gastegger M.; M\u00fcller K.-R.; Tkatchenko A. Combining machine learning and computational chemistry for predictive insights into chemical systems. Chem. Rev. 2021, 121 (16), 9816\u20139872. 10.1021/acs.chemrev.1c00107.", "ArticleIdList": ["10.1021/acs.chemrev.1c00107", "PMC8391798", "34232033"]}, {"Citation": "Moroy G.; Martiny V. Y.; Vayer P.; Villoutreix B. O.; Miteva M. A. Toward in silico structure-based ADMET prediction in drug discovery. Drug Discovery Today 2012, 17 (1\u20132), 44\u201355. 10.1016/j.drudis.2011.10.023.", "ArticleIdList": ["10.1016/j.drudis.2011.10.023", "22056716"]}, {"Citation": "Tielens F.; Gierada M.; Handzlik J.; Calatayud M. Characterization of amorphous silica based catalysts using DFT computational methods. Catal. Today 2020, 354, 3\u201318. 10.1016/j.cattod.2019.03.062.", "ArticleIdList": ["10.1016/j.cattod.2019.03.062"]}, {"Citation": "Pracht P.; Bohle F.; Grimme S. Automated exploration of the low-energy chemical space with fast quantum chemical methods. Phys. Chem. Chem. Phys. 2020, 22 (14), 7169\u20137192. 10.1039/C9CP06869D.", "ArticleIdList": ["10.1039/C9CP06869D", "32073075"]}, {"Citation": "Chalkha M.; Nakkabi A.; Hadda T. B.; Berredjem M.; Moussaoui A. E.; Bakhouch M.; Saadi M.; Ammari L. E.; Almalki F. A.; Laaroussi H.; Jevtovic V.; Yazidi M. E. Crystallographic study, biological assessment and POM/Docking studies of pyrazoles-sulfonamide hybrids (PSH): Identification of a combined Antibacterial/Antiviral pharmacophore sites leading to in-silico screening the anti-Covid-19 activity. J. Mol. Struct. 2022, 1267, 13360510.1016/j.molstruc.2022.133605.", "ArticleIdList": ["10.1016/j.molstruc.2022.133605", "PMC9237569", "35782312"]}, {"Citation": "Elzahabi H. S. A.; Nossier E. S.; Alasfoury R. A.; El-Manawaty M.; Sayed S. M.; Elkaeed E. B.; Metwaly A. M.; Hagras M.; Eissa I. H. Design, synthesis, and anti-cancer evaluation of new pyrido [2, 3-d] pyrimidin-4 (3H)-one derivatives as potential EGFRWT and EGFRT790M inhibitors and apoptosis inducers. J. Enzyme Inhib. Med. Chem. 2022, 37 (1), 1053\u20131076. 10.1080/14756366.2022.2062752.", "ArticleIdList": ["10.1080/14756366.2022.2062752", "PMC9291687", "35821615"]}, {"Citation": "Sobh E. A.; Dahab M. A.; Elkaeed E. B.; Alsfouk A. A.; Ibrahim I. M.; Metwaly A. M.; Eissa I. H. Computer aided drug discovery (CADD) of a thieno[2,3-d]pyrimidine derivative as a new EGFR inhibitor targeting the ribose pocket. J. Biomol. Struct. Dyn. 2023, 42, 2369\u20132391. 10.1080/07391102.2023.2204500.", "ArticleIdList": ["10.1080/07391102.2023.2204500", "37129193"]}, {"Citation": "Elkaeed E. B.; Yousef R. G.; Elkady H.; Alsfouk A. A.; Husein D. Z.; Ibrahim I. M.; Alswah M.; Elzahabi H. S.; Metwaly A. M.; Eissa I. H. A New Theobromine-Based EGFRWT and EGFRT790M Inhibitor and Apoptosis Inducer: Design, Semi-Synthesis, Docking, DFT, MD Simulations, and In Vitro Studies. Processes 2022, 10 (11), 229010.3390/pr10112290.", "ArticleIdList": ["10.3390/pr10112290"]}, {"Citation": "Eissa I. H.; Yousef R. G.; Elkady H.; Alsfouk A. A.; Alsfouk B. A.; Husein D. Z.; Ibrahim I. M.; Elkaeed E. B.; Metwaly A. M. A New Anticancer Semisynthetic Theobromine Derivative Targeting EGFR Protein: CADDD Study. Life 2023, 13 (1), 19110.3390/life13010191.", "ArticleIdList": ["10.3390/life13010191", "PMC9867533", "36676140"]}, {"Citation": "Eissa I. H.; Yousef R. G.; Elkaeed E. B.; Alsfouk A. A.; Husein D. Z.; Ibrahim I. M.; Alesawy M. S.; Elkady H.; Metwaly A. M. Anticancer derivative of the natural alkaloid, theobromine, inhibiting EGFR protein: Computer-aided drug discovery approach. PLoS One 2023, 18 (3), e028258610.1371/journal.pone.0282586.", "ArticleIdList": ["10.1371/journal.pone.0282586", "PMC9997933", "36893122"]}, {"Citation": "Elkaeed E. B.; Yousef R. G.; Elkady H.; Alsfouk A. A.; Husein D. Z.; Ibrahim I. M.; Metwaly A. M.; Eissa I. H. New anticancer theobromine derivative targeting egfrwt and egfrt790m: Design, semi-synthesis, in silico, and in vitro anticancer studies. Molecules 2022, 27 (18), 585910.3390/molecules27185859.", "ArticleIdList": ["10.3390/molecules27185859", "PMC9500845", "36144596"]}, {"Citation": "Eissa I. H.; Yousef R. G.; Elkady H.; Alsfouk A. A.; Husein D. Z.; Ibrahim I. M.; El-Deeb N.; Kenawy A. M.; Eldehna W. M.; Elkaeed E. B. New apoptotic anti-triple-negative breast cancer theobromine derivative inhibiting EGFRWT and EGFRT790M: in silico and in vitro evaluation. Mol. Diversity 2023, 1\u201321. 10.1007/s11030-023-10644-4.", "ArticleIdList": ["10.1007/s11030-023-10644-4", "37162644"]}, {"Citation": "Bonomi P. Erlotinib: a new therapeutic approach for non-small cell lung cancer. Expert Opin. Invest. Drugs 2003, 12 (8), 1395\u20131401. 10.1517/13543784.12.8.1395.", "ArticleIdList": ["10.1517/13543784.12.8.1395", "12882624"]}, {"Citation": "J\u00e4nne P. A.; Yang J. C.-H.; Kim D.-W.; Planchard D.; Ohe Y.; Ramalingam S. S.; Ahn M.-J.; Kim S.-W.; Su W.-C.; Horn L.; et al. AZD9291 in EGFR inhibitor\u2013resistant non\u2013small-cell lung cancer. N. Engl. J. Med. 2015, 372 (18), 1689\u20131699. 10.1056/NEJMoa1411817.", "ArticleIdList": ["10.1056/NEJMoa1411817", "25923549"]}, {"Citation": "Elzahabi H. S. A.; Nossier E. S.; Alasfoury R. A.; El-Manawaty M.; Sayed S. M.; Elkaeed E. B.; Metwaly A. M.; Hagras M.; Eissa I. H. Design, synthesis, and anti-cancer evaluation of new pyrido [2, 3-d] pyrimidin-4 (3H)-one derivatives as potential EGFRWT and EGFRT790M inhibitors and apoptosis inducers. J. Enzyme Inhib. Med. Chem. 2022, 37 (1), 1053\u20131076. 10.1080/14756366.2022.2062752.", "ArticleIdList": ["10.1080/14756366.2022.2062752", "PMC9291687", "35821615"]}, {"Citation": "Gandin V.; Ferrarese A.; Via M. D.; Marzano C.; Chilin A.; Marzaro G. Targeting kinases with anilinopyrimidines: discovery of N-phenyl-N\u2019-[4-(pyrimidin-4-ylamino) phenyl] urea derivatives as selective inhibitors of class III receptor tyrosine kinase subfamily. Sci. Rep. 2015, 5 (1), 1675010.1038/srep16750.", "ArticleIdList": ["10.1038/srep16750", "PMC4645160", "26568452"]}, {"Citation": "Liu Y.; Gray N. S. Rational design of inhibitors that bind to inactive kinase conformations. Nat. Chem. Biol. 2006, 2 (7), 358\u2013364. 10.1038/nchembio799.", "ArticleIdList": ["10.1038/nchembio799", "16783341"]}, {"Citation": "Furet P.; Caravatti G.; Lydon N.; Priestle J. P.; Sowadski J. M.; Trinks U.; Traxler P. Modelling study of protein kinase inhibitors: binding mode of staurosporine and origin of the selectivity of CGP 52411. J. Comput.-Aided Mol. Des. 1995, 9 (6), 465\u2013472. 10.1007/BF00124317.", "ArticleIdList": ["10.1007/BF00124317", "8789188"]}, {"Citation": "Lipinski C. A.; Lombardo F.; Dominy B. W.; Feeney P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Delivery Rev. 1997, 23 (1\u20133), 3\u201325. 10.1016/S0169-409X(96)00423-1.", "ArticleIdList": ["10.1016/S0169-409X(96)00423-1", "11259830"]}, {"Citation": "Chuang K. V.; Gunsalus L. M.; Keiser M. J. Learning molecular representations for medicinal chemistry: miniperspective. J. Med. Chem. 2020, 63 (16), 8705\u20138722. 10.1021/acs.jmedchem.0c00385.", "ArticleIdList": ["10.1021/acs.jmedchem.0c00385", "32366098"]}, {"Citation": "Ferreira L. L. G.; Andricopulo A. D. ADMET modeling approaches in drug discovery. Drug Discovery Today 2019, 24 (5), 1157\u20131165. 10.1016/j.drudis.2019.03.015.", "ArticleIdList": ["10.1016/j.drudis.2019.03.015", "30890362"]}, {"Citation": "Idakwo G.; Luttrell J.; Chen M.; Hong H.; Zhou Z.; Gong P.; Zhang C. A review on machine learning methods for in silico toxicity prediction. J. Environ. Sci. Health, Part C 2018, 36 (4), 169\u2013191. 10.1080/10590501.2018.1537118.", "ArticleIdList": ["10.1080/10590501.2018.1537118", "30628866"]}, {"Citation": "Kruhlak N. L.; Benz R. D.; Zhou H.; Colatsky T. J. (Q)SAR modeling and safety assessment in regulatory review. Clin. Pharmacol. Ther. 2012, 91 (3), 529\u2013534. 10.1038/clpt.2011.300.", "ArticleIdList": ["10.1038/clpt.2011.300", "22258468"]}, {"Citation": "Tice R. R.; Bassan A.; Amberg A.; Anger L. T.; Beal M. A.; Bellion P.; Benigni R.; Birmingham J.; Brigo A.; Bringezu F.; Ceriani L.; Crooks I.; Cross K.; Elespuru R.; Faulkner D. M.; Fortin M. C.; Fowler P.; Frericks M.; Gerets H. H. J.; Jahnke G. D.; Jones D. R.; Kruhlak N. L.; Lo Piparo E.; Lopez-Belmonte J.; Luniwal A.; Luu A.; Madia F.; Manganelli S.; Manickam B.; Mestres J.; Mihalchik-Burhans A. L.; Neilson L.; Pandiri A.; Pavan M.; Rider C. V.; Rooney J. P.; Trejo-Martin A.; Watanabe-Sailor K. H.; White A. T.; Woolley D.; Myatt G. J. In Silico Approaches In Carcinogenicity Hazard Assessment: Current Status and Future Needs. Comput. Toxicol. 2021, 20, 10019110.1016/j.comtox.2021.100191.", "ArticleIdList": ["10.1016/j.comtox.2021.100191", "PMC8967183", "35368437"]}, {"Citation": "Xu C.; Cheng F.; Chen L.; Du Z.; Li W.; Liu G.; Lee P. W.; Tang Y. In silico prediction of chemical Ames mutagenicity. J. Chem. Inf. Model. 2012, 52 (11), 2840\u20132847. 10.1021/ci300400a.", "ArticleIdList": ["10.1021/ci300400a", "23030379"]}, {"Citation": "Thresher A.; Gosling J. P.; Williams R. Generation of TD(50) values for carcinogenicity study data. Toxicol. Res. 2019, 8 (5), 696\u2013703. 10.1039/c9tx00118b.", "ArticleIdList": ["10.1039/c9tx00118b", "PMC6762014", "31588346"]}, {"Citation": "Stampfer H. G.; Gabb G. M.; Dimmitt S. B. Why maximum tolerated dose?. Br. J. Clin. Pharmacol. 2019, 85 (10), 2213\u20132217. 10.1111/bcp.14032.", "ArticleIdList": ["10.1111/bcp.14032", "PMC6783596", "31219196"]}, {"Citation": "Lane T. R.; Harris J.; Urbina F.; Ekins S. Comparing LD(50)/LC(50) Machine Learning Models for Multiple Species. ACS Chem. Health Saf. 2023, 30 (2), 83\u201397. 10.1021/acs.chas.2c00088.", "ArticleIdList": ["10.1021/acs.chas.2c00088", "PMC10348353", "37457397"]}, {"Citation": "Gadaleta D.; Marzo M.; Toropov A.; Toropova A.; Lavado G. J.; Escher S. E.; Dorne J. L. C. M.; Benfenati E. Integrated In Silico Models for the Prediction of No-Observed-(Adverse)-Effect Levels and Lowest-Observed-(Adverse)-Effect Levels in Rats for Sub-chronic Repeated-Dose Toxicity. Chem. Res. Toxicol. 2021, 34 (2), 247\u2013257. 10.1021/acs.chemrestox.0c00176.", "ArticleIdList": ["10.1021/acs.chemrestox.0c00176", "32664725"]}, {"Citation": "Husein D. Z.; Hassanien R.; Khamis M. Cadmium oxide nanoparticles/graphene composite: Synthesis, theoretical insights into reactivity and adsorption study. RSC Adv. 2021, 11 (43), 27027\u201327041. 10.1039/D1RA04754J.", "ArticleIdList": ["10.1039/D1RA04754J", "PMC9037664", "35480026"]}, {"Citation": "Wang T.; Husein D. Z. Novel synthesis of multicomponent porous nano-hybrid composite, theoretical investigation using DFT and dye adsorption applications: Disposing of waste with waste. Environ. Sci. Pollut. Res. 2023, 30, 8928\u20138955. 10.1007/s11356-022-20050-2.", "ArticleIdList": ["10.1007/s11356-022-20050-2", "35460480"]}, {"Citation": "Liu X.; Shi D.; Zhou S.; Liu H.; Liu H.; Yao X. Molecular dynamics simulations and novel drug discovery. Expert Opin. Drug Discovery 2018, 13 (1), 23\u201337. 10.1080/17460441.2018.1403419.", "ArticleIdList": ["10.1080/17460441.2018.1403419", "29139324"]}, {"Citation": "De Vivo M.; Masetti M.; Bottegoni G.; Cavalli A. Role of molecular dynamics and related methods in drug discovery. J. Med. Chem. 2016, 59 (9), 4035\u20134061. 10.1021/acs.jmedchem.5b01684.", "ArticleIdList": ["10.1021/acs.jmedchem.5b01684", "26807648"]}, {"Citation": "Abraham M. J.; Murtola T.; Schulz R.; P\u00e1ll S.; Smith J. C.; Hess B.; Lindahl E. GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX 2015, 1-2, 19\u201325. 10.1016/j.softx.2015.06.001.", "ArticleIdList": ["10.1016/j.softx.2015.06.001"]}, {"Citation": "Brooks B. R.; Brooks C. L. III; Mackerell A. D. Jr; Nilsson L.; Petrella R. J.; Roux B.; Won Y.; Archontis G.; Bartels C.; Boresch S.; et al. CHARMM: the biomolecular simulation program. J. Comput. Chem. 2009, 30 (10), 1545\u20131614. 10.1002/jcc.21287.", "ArticleIdList": ["10.1002/jcc.21287", "PMC2810661", "19444816"]}, {"Citation": "Vald\u00e9s-Tresanco M. S.; Vald\u00e9s-Tresanco M. E.; Valiente P. A.; Moreno E. gmx_MMPBSA: a new tool to perform end-state free energy calculations with GROMACS. J. Chem. Theory Comput. 2021, 17 (10), 6281\u20136291. 10.1021/acs.jctc.1c00645.", "ArticleIdList": ["10.1021/acs.jctc.1c00645", "34586825"]}, {"Citation": "Xiong G.; Shen C.; Yang Z.; Jiang D.; Liu S.; Lu A.; Chen X.; Hou T.; Cao D. Featurization strategies for protein\u2013ligand interactions and their applications in scoring function development. Comput. Mol. Biosci. 2022, 12 (2), e156710.1002/wcms.1567.", "ArticleIdList": ["10.1002/wcms.1567"]}, {"Citation": "Zhao Z.; Bourne P. E. Harnessing systematic protein\u2013ligand interaction fingerprints for drug discovery. Drug Discovery Today 2022, 27, 10331910.1016/j.drudis.2022.07.004.", "ArticleIdList": ["10.1016/j.drudis.2022.07.004", "35850431"]}, {"Citation": "Bouysset C.; Fiorucci S. ProLIF: a library to encode molecular interactions as fingerprints. J. Cheminf. 2021, 13, 7210.1186/s13321-021-00548-6.", "ArticleIdList": ["10.1186/s13321-021-00548-6", "PMC8466659", "34563256"]}, {"Citation": "Salentin S.; Adasme M. F.; Heinrich J. C.; Haupt V. J.; Daminelli S.; Zhang Y.; Schroeder M. From malaria to cancer: Computational drug repositioning of amodiaquine using PLIP interaction patterns. Sci. Rep. 2017, 7 (1), 1140110.1038/s41598-017-11924-4.", "ArticleIdList": ["10.1038/s41598-017-11924-4", "PMC5595859", "28900272"]}, {"Citation": "Salentin S.; Schreiber S.; Haupt V. J.; Adasme M. F.; Schroeder M. PLIP: fully automated protein\u2013ligand interaction profiler. Nucleic Acids Res. 2015, 43 (W1), W443\u2013W447. 10.1093/nar/gkv315.", "ArticleIdList": ["10.1093/nar/gkv315", "PMC4489249", "25873628"]}, {"Citation": "Tubiana T.; Carvaillo J.-C.; Boulard Y.; Bressanelli S. Modeling, TTClust: a versatile molecular simulation trajectory clustering program with graphical summaries. J. Chem. Inf. 2018, 58 (11), 2178\u20132182. 10.1021/acs.jcim.8b00512.", "ArticleIdList": ["10.1021/acs.jcim.8b00512", "30351057"]}, {"Citation": "Papaleo E.; Mereghetti P.; Fantucci P.; Grandori R.; De Gioia L. Free-energy landscape, principal component analysis, and structural clustering to identify representative conformations from molecular dynamics simulations: the myoglobin case. J. Mol. Graphics Modell. 2009, 27 (8), 889\u2013899. 10.1016/j.jmgm.2009.01.006.", "ArticleIdList": ["10.1016/j.jmgm.2009.01.006", "19264523"]}, {"Citation": "David C. C.; Jacobs D. J.. Principal Component Analysis: A Method for Determining the Essential Dynamics of Proteins. In Protein Dynamics: Methods Protocols; Springer, 2014.", "ArticleIdList": ["PMC4676806", "24061923"]}, {"Citation": "Maisuradze G. G.; Leitner D. M. Free energy landscape of a biomolecule in dihedral principal component space: Sampling convergence and correspondence between structures and minima. Proteins: Struct., Funct., Bioinf. 2007, 67 (3), 569\u2013578. 10.1002/prot.21344.", "ArticleIdList": ["10.1002/prot.21344", "17348026"]}, {"Citation": "Hess B. Similarities between principal components of protein dynamics and random diffusion. Phys. Rev. E 2000, 62 (6), 843810.1103/PhysRevE.62.8438.", "ArticleIdList": ["10.1103/PhysRevE.62.8438", "11138145"]}, {"Citation": "Eissa I. H.; Yousef R. G.; Elkady H.; Alsfouk A. A.; Alsfouk B. A.; Husein D. Z.; Ibrahim I. M.; Elkaeed E. B.; Metwaly A. M. A New Anticancer Semisynthetic Theobromine Derivative Targeting EGFR Protein: CADDD Study. Life 2023, 13 (1), 19110.3390/life13010191.", "ArticleIdList": ["10.3390/life13010191", "PMC9867533", "36676140"]}, {"Citation": "Obeng E. Apoptosis (programmed cell death) and its signals-A review. Braz. J. Biol. 2021, 81, 1133\u20131143. 10.1590/1519-6984.228437.", "ArticleIdList": ["10.1590/1519-6984.228437", "33111928"]}, {"Citation": "Wyllie A. H. Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature 1980, 284, 555\u2013556. 10.1038/284555a0.", "ArticleIdList": ["10.1038/284555a0", "6245367"]}, {"Citation": "Alanazi M. M.; Eissa I. H.; Alsaif N. A.; Obaidullah A. J.; Alanazi W. A.; Alasmari A. F.; Albassam H.; Elkady H.; Elwan A. Design, synthesis, docking, ADMET studies, and anticancer evaluation of new 3-methylquinoxaline derivatives as VEGFR-2 inhibitors and apoptosis inducers. J. Enzyme Inhib. Med. Chem. 2021, 36 (1), 1760\u20131782. 10.1080/14756366.2021.1956488.", "ArticleIdList": ["10.1080/14756366.2021.1956488", "PMC8344243", "34340610"]}, {"Citation": "Porter A. G.; J\u00e4nicke R. U. Emerging roles of caspase-3 in apoptosis. Cell Death Differ. 1999, 6 (2), 99\u2013104. 10.1038/sj.cdd.4400476.", "ArticleIdList": ["10.1038/sj.cdd.4400476", "10200555"]}, {"Citation": "Li P.; Zhou L.; Zhao T.; Liu X.; Zhang P.; Liu Y.; Zheng X.; Li Q. Caspase-9: structure, mechanisms and clinical application. Oncotarget 2017, 8 (14), 23996\u201324008. 10.18632/oncotarget.15098.", "ArticleIdList": ["10.18632/oncotarget.15098", "PMC5410359", "28177918"]}, {"Citation": "Shacter E.; Weitzman S. A. Chronic inflammation and cancer. Oncology 2002, 16 (2), 217\u2013226.", "ArticleIdList": ["11866137"]}, {"Citation": "Angelo L. S.; Kurzrock R. Vascular endothelial growth factor and its relationship to inflammatory mediators. Clin. Cancer Res. 2007, 13 (10), 2825\u20132830. 10.1158/1078-0432.CCR-06-2416.", "ArticleIdList": ["10.1158/1078-0432.CCR-06-2416", "17504979"]}, {"Citation": "Roberti M. P.; Barrio M. M.; Bravo A.; Rocca Y.; Arriaga J. M.; Bianchini M.; Mordoh J.; Levy E. M. J. B. c. r. IL-15 and IL-2 increase Cetuximab-mediated cellular cytotoxicity against triple negative breast cancer cell lines expressing EGFR. Breast Cancer Res. Treat. 2011, 130, 465\u2013475. 10.1007/s10549-011-1360-2.", "ArticleIdList": ["10.1007/s10549-011-1360-2", "21308409"]}, {"Citation": "Shibuya H.; Yoneyama M.; Ninomiya-Tsuji J.; Matsumoto K.; Taniguchi T. IL-2 and EGF receptors stimulate the hematopoietic cell cycle via different signaling pathways: demonstration of a novel role for c-myc. Cell 1992, 70 (1), 57\u201367. 10.1016/0092-8674(92)90533-I.", "ArticleIdList": ["10.1016/0092-8674(92)90533-I", "1535827"]}, {"Citation": "Lee C.-W.; Lin C.-C.; Lin W.-N.; Liang K.-C.; Luo S.-F.; Wu C.-B.; Wang S.-W.; Yang C.-M. TNF-\u03b1 induces MMP-9 expression via activation of Src/EGFR, PDGFR/PI3K/Akt cascade and promotion of NF-\u03baB/p300 binding in human tracheal smooth muscle cells. Am. J. Physiol.: Lung Cell. Mol. Physiol. 2007, 292 (3), L799\u2013L812. 10.1152/ajplung.00311.2006.", "ArticleIdList": ["10.1152/ajplung.00311.2006", "17158602"]}, {"Citation": "Suleimen Y. M.; Jose R. A.; Mamytbekova G. K.; Suleimen R. N.; Ishmuratova M. Y.; Dehaen W.; Alsfouk B. A.; Elkaeed E. B.; Eissa I. H.; Metwaly A. M. Isolation and In Silico Inhibitory Potential against SARS-CoV-2 RNA Polymerase of the Rare Kaempferol 3-O-(6 \u2033-O-acetyl)-Glucoside from Calligonum tetrapterum. Plants 2022, 11 (15), 207210.3390/plants11152072.", "ArticleIdList": ["10.3390/plants11152072", "PMC9370365", "35956550"]}, {"Citation": "Jo S.; Cheng X.; Islam S. M.; Huang L.; Rui H.; Zhu A.; Lee H. S.; Qi Y.; Han W.; Vanommeslaeghe K.. et al.CHARMM-GUI PDB manipulator for advanced modeling and simulations of proteins containing nonstandard residues. In Advances in Protein Chemistry Structural Biology; Elsevier, 2014.", "ArticleIdList": ["PMC4739825", "25443960"]}, {"Citation": "Vald\u00e9s-Tresanco M. S.; Vald\u00e9s-Tresanco M. E.; Valiente P. A.; Moreno E. gmx_MMPBSA: A New Tool to Perform End-State Free Energy Calculations with GROMACS. J. Chem. Theory Comput. 2021, 17 (10), 6281\u20136291. 10.1021/acs.jctc.1c00645.", "ArticleIdList": ["10.1021/acs.jctc.1c00645", "34586825"]}, {"Citation": "Amadei A.; Linssen A. B.; Berendsen H. J. Essential dynamics of proteins. Proteins: Struct., Funct., Bioinf. 1993, 17 (4), 412\u2013425. 10.1002/prot.340170408.", "ArticleIdList": ["10.1002/prot.340170408", "8108382"]}, {"Citation": "Syst\u00e8mes, Dassault. \u201cBiovia, discovery studio modeling environment.\u201d Dassault Syst\u00e8mes Biovia: San Diego, CA, USA: (2017)."}, {"Citation": "Yousef R. G.; Elwan A.; Gobaara I. M.; Mehany A. B.; Eldehna W. M.; El-Metwally S. A.; A Alsfouk B.; Elkaeed E. B.; Metwaly A. M.; Eissa I. H. Anti-cancer and immunomodulatory evaluation of new nicotinamide derivatives as potential VEGFR-2 inhibitors and apoptosis inducers: in vitro and in silico studies. J. Enzyme Inhib. Med. Chem. 2022, 37 (1), 2206\u20132222. 10.1080/14756366.2022.2110868.", "ArticleIdList": ["10.1080/14756366.2022.2110868", "PMC9466619", "35980113"]}, {"Citation": "Alley M. C.; Scudiero D. A.; Monks A.; Hursey M. L.; Czerwinski M. J.; Fine D. L.; Abbott B. J.; Mayo J. G.; Shoemaker R. H.; Boyd M. R. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res. 1988, 48 (3), 589\u2013601.", "ArticleIdList": ["3335022"]}, {"Citation": "Van de Loosdrecht A.; Beelen R.; Ossenkoppele g.; Broekhoven M.; Langenhuijsen M. A tetrazolium-based colorimetric MTT assay to quantitate human monocyte mediated cytotoxicity against leukemic cells from cell lines and patients with acute myeloid leukemia. J. Immunol. Methods 1994, 174 (1\u20132), 311\u2013320. 10.1016/0022-1759(94)90034-5.", "ArticleIdList": ["10.1016/0022-1759(94)90034-5", "8083535"]}, {"Citation": "Koch A.; Tamez P.; Pezzuto J.; Soejarto D. Evaluation of plants used for antimalarial treatment by the Maasai of Kenya. J. Ethnopharmacol. 2005, 101 (1\u20133), 95\u201399. 10.1016/j.jep.2005.03.011.", "ArticleIdList": ["10.1016/j.jep.2005.03.011", "15878245"]}]}], "History": [{"Year": "2023", "Month": "10", "Day": "17"}, {"Year": "2024", "Month": "3", "Day": "6"}, {"Year": "2024", "Month": "3", "Day": "12"}, {"Year": "2024", "Month": "4", "Day": "15", "Hour": "6", "Minute": "44"}, {"Year": "2024", "Month": "4", "Day": "15", "Hour": "6", "Minute": "43"}, {"Year": "2024", "Month": "4", "Day": "15", "Hour": "4", "Minute": "21"}, {"Year": "2024", "Month": "3", "Day": "27"}], "PublicationStatus": "epublish", "ArticleIdList": ["38617602", "PMC11007702", "10.1021/acsomega.3c08148"]}}]}